Evaxion A/S filings document a foreign private issuer that furnishes Form 6-K reports for business updates, financial results, clinical and preclinical vaccine-program disclosures, and governance actions. Recent reports describe AI-Immunology™-powered vaccine development, EVX-01 personalized cancer vaccine data in advanced melanoma, platform work in glioblastoma, and infectious disease vaccine design concepts.
The filing record also includes annual general meeting results, approval of the audited annual report, board and auditor elections, leadership-role disclosures, and incorporation of Form 6-K reports by reference into Form S-8, Form F-1, and Form F-3 registration statements. These documents frame Evaxion’s capital-market disclosures around pipeline development, corporate governance, securities registrations, and recurring operating updates.
Evaxion A/S, a clinical-stage TechBio company using AI-Immunology, furnished a press release announcing it will provide a business update and publish its second-quarter 2025 financial results on August 14, 2025. The Form 6-K states the press release is furnished as Exhibit 99.1 to the filing.
The filing itself contains no financial figures, operational metrics, or transaction details; it serves to notify investors of the timing and availability of the forthcoming update and results announcement.
Evaxion A/S (NASDAQ: EVAX) filed a Form 6-K on 11 July 2025 to furnish a press release announcing that the Company has finalized an agreement with the European Investment Bank (EIB) to convert existing debt into equity. The press release, provided as Exhibit 99.1, is the only substantive disclosure contained in the filing. No additional terms, financial amounts, or timing details are included in the 6-K.
Evaxion (NASDAQ: EVAX) filed a Form 6-K furnishing a June 25, 2025 press release entitled “Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus.” The document reports that the clinical-stage TechBio company is adding a Group A Strep prophylactic candidate to its AI-Immunology-powered vaccine portfolio.
The submission is informational only: it contains no financial statements, guidance, capital-raising details, or clinical timelines. The press release (Exhibit 99.1) is incorporated by reference into multiple outstanding registration statements (Forms S-8, F-1 and F-3), ensuring that future prospectuses automatically reflect the new program.
There are no disclosures of changes in management, litigation, risk factors, or business strategy beyond the stated pipeline expansion. Accordingly, the filing signals strategic breadth but offers limited quantifiable data for investors to model near-term cash requirements or milestones.